Voluntary recall of hemophilus influenza type b conjugate vaccine "ActHIB®"

Voluntary recall of hemophilus influenza type b conjugate vaccine "ActHIB®"

To the attention of the Press :
March 11, 2011
Sanofi Pasteur KK
Daiichi Sankyo Co., Ltd.

Sanofi Pasteur KK (Head Office: Shinjuku-ku, Tokyo; Representative Director and President: Franck Perraudin, hereinafter "Sanofi Pasteur") and Daiichi Sankyo Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director and President and CEO: Joji Nakayama, hereinafter "Daiichi Sankyo") have decided to voluntarily recall part of the products "ActHIB®" (generic name: hemophilus influenza type b conjugate vaccine) which are manufactured and marketed by Sanofi Pasteur and distributed by Daiichi Sankyo. This voluntary recall of some ActHIB products is due to a notification of contamination by foreign matter and the resulting investigation which confirmed two cases of contamination inside syringes of diluent which are used to reconstitute ActHIB.
As a result of analysis of information by Sanofi Pasteur up to the present time, it has been confirmed that the foreign matter was aseptic (nonbacterial). However, in order to eliminate every possible risk, it was decided to voluntarily recall the ActHIB products which were manufactured in the same manufacturing process as the syringes in which the foreign matter was confirmed starting today.
Please allow us to express our sincere apologies for the inconveniences and concern this recall may cause to health professionals and families of infants eligible for immunization with "ActHIB®." Sanofi Pasteur will endeavor to find the cause of this matter and prevent recurrences of the incidence by reviewing quality measures at the production stage. Your understanding of the present voluntary recall would be much appreciated.
Lot numbers of products subject to recall:
Sanofi Pasteur KK
Vaccine Advocacy and Public Affairs
Masumi IWAMA
Tel: 03-6301-3089
Daiichi Sankyo Co., Ltd.
Corporate Communication Department
Tel: 03-6225-1126

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.